Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Lehmann, Maria ^a   Hoffmann, Michèle J ^a   Koch, Annemarie ^a   Ulrich, Scott M ^b   Schulz, Wolfgang A ^a   Niegisch, Günter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b ITHACA COLLEGE   (United States)

Author keywords

Cell cycle arrest; Histone deacetylase 8; Histone deacetylase inhibitor; Urothelial bladder cancer

Indexed keywords

HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; SMALL INTERFERING RNA; THYMIDYLATE SYNTHASE; HDAC8 PROTEIN, HUMAN; HISTONE DEACETYLASE; HYDROXAMIC ACID; REPRESSOR PROTEIN;

ARTICLE; ATPASE ACTIVITY ASSAY; CELL GROWTH; CELL MIGRATION ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRANSITIONAL CELL CARCINOMA; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; GENE SILENCING; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MOLECULAR TARGETED THERAPY; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; URINARY BLADDER NEOPLASMS;

EID: 84904080238     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-014-0059-8     Document Type: Article

References (48)

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. J Ferlay, HR Shin, F Bray, D Forman, C Mathers, DM Parkin, Int J Cancer 2010 127 2893 2917 10.1002/ijc.25516 21351269
2. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines. JA Witjes, E Comperat, NC Cowan, M De Santis, G Gakis, T Lebret, MJ Ribal, AG Van der Heijden, A Sherif, Eur Urol 2014 65 4 778 92 10.1016/j.eururo.2013.11.046 24373477
3. Noninvasive and invasive bladder cancer: diagnostics and treatment. PJ Goebell, F Vom Dorp, C Rodel, D Frohneberg, JW Thuroff, D Jocham, C Stief, S Roth, R Knuchel, KW Schmidt, I Kausch, D Zaak, C Wiesner, K Miller, R Sauer, H Rübben, Der Urologe Ausg A 2006 45 873 884 10.1007/s00120-006-1065-z 16791629
4. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. JT Roberts, H von der Maase, L Sengelov, PF Conte, L Dogliotti, T Oliver, MJ Moore, A Zimmermann, M Arning, Ann Oncol 2006 17 Suppl 5 &22118 122 10.1093/annonc/mdj965 16807438
5. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. CN Sternberg, J Bellmunt, G Sonpavde, AO Siefker-Radtke, WM Stadler, DF Bajorin, R Dreicer, DJ George, MI Milowsky, D Theodorescu, DJ Vaughn, MD Galsky, MS Soloway, DI Quinn, Eur Urol 2013 63 58 66 10.1016/j.eururo.2012.08.010 22917984
6. Histone-modifying enzymes: regulators of developmental decisions and drivers of human disease. JS Butler, E Koutelou, AC Schibler, SY Dent, Epigenomics 2012 4 163 177 10.2217/epi.12.3 22449188
7. Cancer epigenetics: from mechanism to therapy. MA Dawson, T Kouzarides, Cell 2012 150 12 27 10.1016/j.cell.2012.06.013 22770212
8. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Y Gui, G Guo, Y Huang, X Hu, A Tang, S Gao, R Wu, C Chen, X Li, L Zhou, M He, Z Li, X Sun, W Jia, J Chen, S Yang, F Zhou, X Zhao, S Wan, R Ye, C Liang, Z Liu, P Huang, C Liu, H Jiang, Y Wang, H Zheng, L Sun, X Liu, Z Jiang, et al. Nat Genet 2011 43 875 878 10.1038/ng.907 21822268
9. Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy. M Ahmad, A Hamid, A Hussain, R Majeed, Y Qurishi, JA Bhat, RA Najar, AK Qazi, MA Zargar, SK Singh, AK Saxena, DNA Cell Biol 2012 31 Suppl 1 62 71 22462686
10. Histone deacetylases and cancer: causes and therapies. P Marks, RA Rifkind, VM Richon, R Breslow, T Miller, WK Kelly, Nat Rev Canc 2001 1 194 202 10.1038/35106079
11. Histone deacetylases (HDACs): characterization of the classical HDAC family. AJ de Ruijter, AH van Gennip, HN Caron, S Kemp, AB van Kuilenburg, Biochem J 2003 370 737 749 10.1042/BJ20021321 12429021
12. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. IV Gregoretti, YM Lee, HV Goodson, J Mol Biol 2004 338 17 31 10.1016/j.jmb.2004.02.006 15050820
13. HDAC family: What are the cancer relevant targets? O Witt, HE Deubzer, T Milde, I Oehme, Cancer Lett 2009 277 8 21 10.1016/j.canlet.2008.08.016 18824292
14. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. W Weichert, A Roske, V Gekeler, T Beckers, MP Ebert, M Pross, M Dietel, C Denkert, C Rocken, Lancet Oncol 2008 9 139 148 10.1016/S1470-2045(08)70004-4 18207460
15. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. W Weichert, A Roske, V Gekeler, T Beckers, C Stephan, K Jung, FR Fritzsche, S Niesporek, C Denkert, M Dietel, G Kristiansen, Br J Cancer 2008 98 604 610 10.1038/sj.bjc.6604199 18212746
16. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. W Weichert, C Denkert, A Noske, S Darb-Esfahani, M Dietel, SE Kalloger, DG Huntsman, M Kobel, Neoplasia 2008 10 1021 1027 18714364
17. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. XJ Yang, E Seto, Nat Rev Mol Cell Biol 2008 9 206 218 10.1038/nrm2346 18292778
18. Histone acetylation in chromatin structure and transcription. M Grunstein, Nature 1997 389 349 352 10.1038/38664 9311776
19. Lysine acetylation targets protein complexes and co-regulates major cellular functions. C Choudhary, C Kumar, F Gnad, ML Nielsen, M Rehman, TC Walther, JV Olsen, M Mann, Science 2009 325 834 840 10.1126/science.1175371 19608861
20. The biology of lysine acetylation integrates transcriptional programming and metabolism. J Patel, RR Pathak, S Mujtaba, Nutr Metabol 2011 8 12 10.1186/1743-7075-8-12
21. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. W Gu, RG Roeder, Cell 1997 90 595 606 10.1016/S0092-8674(00) 80521-8 9288740
22. Eco1-dependent cohesin acetylation during establishment of sister chromatid cohesion. T Rolef Ben-Shahar, S Heeger, C Lehane, P East, H Flynn, M Skehel, F Uhlmann, Science 2008 321 563 566 10.1126/science.1157774 18653893
23. Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. Y Li, D Shin, SH Kwon, FEBS J 2013 280 775 793 23181831
24. Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011-2013). S Valente, A Mai, Expert Opin Ther Pat 2014 24 4 401 15 10.1517/13543776.2014.877446 24397271
25. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. K Ververis, A Hiong, TC Karagiannis, PV Licciardi, Biologics 2013 7 47 60 23459471
26. Expression profile of class I histone deacetylases in human cancer tissues. M Nakagawa, Y Oda, T Eguchi, S Aishima, T Yao, F Hosoi, Y Basaki, M Ono, M Kuwano, M Tanaka, M Tsuneyoshi, Oncol Rep 2007 18 769 774 17786334
27. Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. E Hu, Z Chen, T Fredrickson, Y Zhu, R Kirkpatrick, GF Zhang, K Johanson, CM Sung, R Liu, J Winkler, J Biol Chem 2000 275 15254 15264 10.1074/jbc.M908988199 10748112
28. Cloning and characterization of human histone deacetylase 8. I Van den Wyngaert, W de Vries, A Kremer, J Neefs, P Verhasselt, WH Luyten, SU Kass, FEBS Lett 2000 478 77 83 10.1016/S0014-5793(00)01813-5 10922473
29. Cloning and characterization of a novel human histone deacetylase, HDAC8. JJ Buggy, ML Sideris, P Mak, DD Lorimer, B McIntosh, JM Clark, Biochem J 2000 350 Pt 1 199 205 10.1042/0264-6021:3500199 10926844
30. Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A. H Lee, N Rezai-Zadeh, E Seto, Mol Cell Biol 2004 24 765 773 10.1128/MCB.24.2.765-773.2004 14701748
31. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. A Vannini, C Volpari, G Filocamo, EC Casavola, M Brunetti, D Renzoni, P Chakravarty, C Paolini, R De Francesco, P Gallinari, C Steinkühler, S Di Marco, Proc Natl Acad Sci U S A 2004 101 15064 15069 10.1073/pnas.0404603101 15477595
32. Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells. D Waltregny, B North, F Van Mellaert, J de Leval, E Verdin, V Castronovo, Eur J Histochem 2004 48 273 290 15590418
33. Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. D Waltregny, L De Leval, W Glenisson, S Ly Tran, BJ North, A Bellahcene, U Weidle, E Verdin, V Castronovo, Am J Pathol 2004 165 553 564 10.1016/S0002-9440(10)63320-2 15277229
34. Histone deacetylase 8 in neuroblastoma tumorigenesis. I Oehme, HE Deubzer, D Wegener, D Pickert, JP Linke, B Hero, A Kopp-Schneider, F Westermann, SM Ulrich, A von Deimling, M Fischer, O Witt, Clin Cancer Res 2009 15 91 99 10.1158/1078-0432.CCR-08-0684 19118036
35. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. S Balasubramanian, J Ramos, W Luo, M Sirisawad, E Verner, JJ Buggy, Leukemia 2008 22 1026 1034 10.1038/leu.2008.9 18256683
36. The up-regulation of histone deacetylase 8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma. J Wu, C Du, Z Lv, C Ding, J Cheng, H Xie, L Zhou, S Zheng, Dig Dis Sci 2013 58 3545 3553 10.1007/s10620-013-2867-7 24077923
37. Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. SY Park, JA Jun, KJ Jeong, HJ Heo, JS Sohn, HY Lee, CG Park, J Kang, Oncol Rep 2011 25 1677 1681 21455583
38. Histone deacetylase 8 safeguards the human ever-shorter telomeres 1B (hEST1B) protein from ubiquitin-mediated degradation. H Lee, N Sengupta, A Villagra, N Rezai-Zadeh, E Seto, Mol Cell Biol 2006 26 5259 5269 10.1128/MCB.01971-05 16809764
39. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. G Niegisch, J Knievel, A Koch, C Hader, U Fischer, P Albers, WA Schulz, Urol Oncol 2013 31 1770 1779 10.1016/j.urolonc.2012.06.015 22944197
40. Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. S Swiatkowski, HH Seifert, C Steinhoff, A Prior, I Thievessen, F Schliess, WA Schulz, Exp Cell Res 2003 282 48 57 10.1006/excr.2002.5647 12490193
41. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. K Krennhrubec, BL Marshall, M Hedglin, E Verdin, SM Ulrich, Bioorg Med Chem Lett 2007 17 2874 2878 10.1016/j.bmcl.2007.02.064 17346959
42. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. I Nicoletti, G Migliorati, MC Pagliacci, F Grignani, C Riccardi, J Immunol Meth 1991 139 271 279 10.1016/0022-1759(91) 90198-O
43. Extraction, purification and analysis of histones. D Shechter, HL Dormann, CD Allis, SB Hake, Nat Protocol 2007 2 1445 1457 10.1038/nprot.2007.202
44. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. JS Lee, SH Leem, SY Lee, SC Kim, ES Park, SB Kim, SK Kim, YJ Kim, WJ Kim, IS Chu, J Clin Oncol 2010 28 2660 2667 10.1200/JCO.2009.25.0977 20421545
45. Effects of Targeting Endometrial Stromal Sarcoma Cells via Histone Deacetylase and PI3K/AKT/mTOR Signaling. P Quan, F Moinfar, I Kufferath, M Absenger, T Kueznik, H Denk, K Zatloukal, J Haybaeck, Anticancer Res 2014 34 2883 2897 24922651
46. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. C Boyault, K Sadoul, M Pabion, S Khochbin, Oncogene 2007 26 5468 5476 10.1038/sj.onc.1210614 17694087
47. Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line. Y Yagi, S Fushida, S Harada, J Kinoshita, I Makino, K Oyama, H Tajima, H Fujita, H Takamura, I Ninomiya, T Fujimura, T Ohta, M Yashiro, K Hirakawa, J Exp Clin Cancer Res 2010 29 149 10.1186/1756-9966-29-149 21080974
48. Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells. L Rosik, G Niegisch, U Fischer, M Jung, WA Schulz, MJ Hoffmann, Canc Biol Ther 2014 15 742 57 10.4161/cbt.28469